Mirati Therapeutics, Inc. (MRTX)
(Delayed Data from NSDQ)
$63.93 USD
+2.52 (4.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $64.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRTX 63.93 +2.52(4.10%)
Will MRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRTX
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
MRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B